Finanzen von bluebird bio Inc (BLUE)BLUEbluebird bio Inc

Evaluating the bottom line, bluebird bio Inc maintains a gross margin of 68.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -55.56%, while the net margin is -75.09%. These profitability ratios, combined with a Return on Equity (ROE) of -546.54%, provide a clear picture of how effectively BLUE converts its operational activities into shareholder value.

In the context of the broader market, BLUE competes directly with industry leaders such as KLRS and STTK. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BLUE's gross margin of 68.39% stands against KLRS's N/A and STTK's N/A. Such benchmarking helps identify whether bluebird bio Inc is trading at a premium or discount relative to its financial performance.